PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Becotatug Vedotin

Drugs in development · updated 30 October 2026

Becotatug Vedotin: clinical trials and development status

Other names and codes: MRG003

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Feb 2029 – Dec 2029 (Phuturdex estimate)

As of 30 October 2026 Becotatug Vedotin is in 61 active clinical trials (recruiting or ongoing, phases I–III) for 27 diseases. The most advanced phase is III.

61Active trials
IIIMost advanced phase
27Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Becotatug Vedotin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Head and neck squamous cell carcinomaIII14NCT05751512
Nasopharyngeal CarcinomaIII9NCT06976190
CholangiocarcinomaII–III1NCT07598318
Penile neoplasmII4NCT07497919
Head and neck neoplasmsII3NCT07766889
Biliary tract neoplasmII2NCT07890311
Esophageal squamous cell carcinomaII2NCT07686926
MetastasisII2NCT07424664
Non-small-cell lung carcinomaII2NCT07882940
Thyroid neoplasmII2NCT07874321
AdenocarcinomaII1NCT07692334
Adenoid cystic carcinomaII1NCT07522879
Breast neoplasmII1NCT07825753
CarcinomaII1NCT07844551
Colorectal neoplasmII1NCT07884188
Nasopharyngeal neoplasmII1NCT07524413
NeoplasmII1NCT07874321
Pancreatic neoplasmII1NCT07825753
Stomach neoplasmII1NCT07692334
Uterine cervix neoplasmII1NCT07424664
Vaginal neoplasmII1NCT07424664
Vulvar neoplasmII1NCT07424664
MedulloblastomaI1NCT07584499
NeuroblastomaI1NCT07584499
Rhabdoid tumorI1NCT07584499
RhabdomyosarcomaI1NCT07584499
Wilms TumorI1NCT07584499

Everything on Becotatug Vedotin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch